Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05522868
PHASE1
SB17170 Phase 1 Clinical Trial in Solid Tumors
Sponsor: SPARK Biopharma
View on ClinicalTrials.gov
Summary
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Official title: An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK/PD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2022-10-17
Completion Date
2027-12-30
Last Updated
2025-11-20
Healthy Volunteers
No
Conditions
Interventions
DRUG
SB17170
SB17170 capsules, Oral administration 21days/cycle
Locations (3)
Asan Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea